US-based healthcare firm Abbott has completed the acquisition of medical device company Topera for $250m.
Topera develops electrophysiology technologies to improve the diagnosis and treatment of atrial fibrillation (AF), one of the most common heart rhythm disorders worldwide.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
With this acquisition, Abbott enters the $3bn catheter-based electrophysiology market that has grown annually at double-digit rates.
Abbott medical devices executive vice-president John Capek said: “The Topera acquisition gives Abbott a foundational entry in the large, high-growth electrophysiology market with breakthrough technologies that can transform how physicians treat people with complex heart rhythm disorders.
“The ability to more accurately target the areas of the heart perpetuating atrial fibrillation is a significant advancement in the field of electrophysiology and can transform patient care.”
A new diagnostic catheter and mapping software or rotor identification system developed by Topera allows physicians to identify target patient-specific rotors shown to be the sustaining mechanism for atrial fibrillation.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe rotor system features RhythmView workstation and FIRMap diagnostic catheter, which helps physicians identify and locate rotors, the specific areas within the heart acting as a sustaining mechanism for AF.
RhythmView workstation and FIRMap diagnostic catheter obtained US Food and Drug Administration (FDA) and CE Mark approval in 2013.
Abbott also secured the right to buy Advanced Cardiac Therapeutics (ACT), in a separate transaction. ACT is involved in developing an ablation catheter designed to improve the safety and effectiveness of ablation procedures.
